HIV Treatment Bulletin - Vol. 7, No. 11/12, November/December 2006

The Clinton Foundation announced a deal with Cipla and Ranbaxy to make 19 antiretroviral products available for treating paediatric HIV at an average price of $60 a year.

The statement from the foundation says that these prices will be available to 62 developing countries and will make treatment possible for an additional 100,000 people in 2007.

$15 million from the Clinton Foundation and a further $35 million grant Unitaid, a drug purchasing consortium, formed in September by France, Brazil, Chile, Norway and the UK, will be combined to assure the Indian generic companies sufficient volume of drug sales to justify the lower prices.

Antiretroiral products to be purchased include new fixed dose combinations (FDCs) Pedimune and Triviro-LNS kids for older children (see HTB volume 7 number 9 page 15-16).

These formulations still need to be licenced and pre-qualified by the WHO.

The WHO has produced simple dosing tables for each product for children based on weight bands. http://www.who.int/entity/hiv/paediatric/generictool.xls.

2006-11-10
IB060711-18

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.